The prostaglandin pathway is activated in patients who fail medical therapy for benign prostatic hyperplasia with lower urinary tract symptoms
The Prostate2021Vol. 81(13), pp. 944–955
Citations Over TimeTop 14% of 2021 papers
R. Jin, Douglas W. Strand, Connor M. Forbes, Thomas C. Case, Justin Cates, Qi Liu, Marisol Ramirez‐Solano, Ginger L. Milne, Stephanie Sanchez, Zunyi Wang, Dale E. Bjorling, Nicole L. Miller, Robert J. Matusik
Abstract
Treatment of BPH/LUTS by inhibition of alpha-adrenergic receptors with pharmaceutical α-blockers or inhibiting androgenesis with 5ARI may fail because of elevated paracrine signaling by prostatic PGs that can cause smooth muscle contraction. In contrast to patients who fail medical therapy for BPH/LUTS, control I-BPH patients do not show the same evidence of elevated PG pathway signaling. Elevation of the PG pathway may explain, in part, why the risk of clinical progression in the MTOPS study was only reduced by 34% with α-blocker treatment.
Related Papers
- → Outcomes of Aquablation in Men With Acute and Chronic Urinary Retention(2023)3 cited
- → Re: Proportion of Tadalafil-Treated Patients with Clinically Meaningful Improvement in Lower Urinary Tract Symptoms Associated with Benign Prostatic Hyperplasia—Integrated Data from 1,499 Study Participants(2015)
- Drug choices reviewed for benign prostatic hyperplasia(2016)
- Drug choices reviewed for benign prostatic hyperplasia : review(2016)
- → UP-3.047: Relationship between Lower Urinary Tract Symptoms and Intraprostatic Inflammation for Patients with Benign Prostatic Hyperplasia(2009)